SP-0688 Against the motion: we don’t need Costalotamab when we have SBRT

Acute stroke: we have the treatments and we have the evidence – we need to use them

Despite huge global burden, stroke disease has traditionally received little attention in the general medical press. We review a series of four acute stroke research articles published in a themed issue of the Lancet. Claiborne-Johnston and coworkers presented a scoring system to stratify risk of stroke following transient ischaemic attack. Chalela and colleagues demonstrated that magnetic reso...

Networking Languages: What We Need and What We Have Networking Languages: What We Need and What We Have

Widespread availability of network access and networked information systems has created a high demand for new generation multi-protocol aware information browsing and presentation tools. In order to support eecient programming and operation for such tools, new networking languages will need to be employed. This study attempts to identify requirements for these networking languages and their env...

How do we change practice when we have the evidence?

Translating research findings into practice includes myriad pragmatic realities, including understanding the suitability of the data to a particular patient group, writing new guidelines for occupational therapy practitioners, facilitating adoption of the guidelines, and instituting new patterns of care for patients. The process is more than a matter of disseminating the information to practiti...

Population Equation: Balancing What We Need With What We Have

What We Have Learned and What We Need to Know

s and Treatment Recommendations Abstract: Stem Cell Transplantation in the Therapy of ALL in Children [1] Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute Table 1. Grading the Quality of Design and Strength of Evidence Stem Cell Transplantation in the Therapy of ALL in Children [1] Evidence supporting the role of hematopoietic stem cell trans...